We previously revealed that Choreito, a traditional Kampo medicine, strongly inhibits bladder carcinogenesis promotion. We have also shown that Polyporus sclerotium, which is one of the crude drugs in Choreito, has the strongest bladder carcinogenesis inhibitory effect and that the ergosterol contained in Polyporus sclerotium is the main active component. In this study, we analyzed the mechanism by which ergosterol inhibits bladder carcinogenesis. Rats were given an N-butyl-N-(4-hydroxybutyl) nitrosamine (BHBN) solution ad libitum, and then a promoter [saccharin sodium (SS), DL-tryptophan, or BHBN] was administered together with ergosterol or its metabolite, brassicasterol. The bladders were removed from rats, and the inhibitory effect on carcinogenesis promotion was evaluated by an agglutination assay with concanavalin A (Con A). Although the oral administration of ergosterol inhibited the promotion of bladder carcinogenesis with SS, the intraperitoneal administration of brassicasterol showed a stronger effect. The effect of brassicasterol on carcinogenesis promotion was observed regardless of the type of promoter. Administration of testosterone to castrated rats increased the number of cell aggregates caused by Con A. In contrast, intraperitoneal administration of brassicasterol to castrated rats treated with testosterone significantly decreased the number of cell aggregates, confirming the inhibition of bladder carcinogenesis promotion. The inhibitory effect of ergosterol on bladder carcinogenesis is due to brassicasterol, a metabolite of ergosterol. The action of brassicasterol via androgen signaling may play a role in the inhibitory effect on bladder carcinogenesis promotion.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
DeGeorge KC, Holt HR, Hodges SC (2017) Bladder cancer: diagnosis and treatment. Am Fam Phys 96:507–514
Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM (2016) The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther 16:255–271
Unda-Urzaiz M, Fernandez-Gomez JM, Cozar-Olmo JM, Juarez A, Palou J, Martinez-Pineiro L (2018) Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer. Actas Urol Esp 42:73–76
Guallar-Garrido S, Julian E (2020) Bacillus calmette-guerin (bcg) therapy for bladder cancer: an update. Immuno Ther 9:1–11
Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol 116:180–183
Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European Union. Eur Urol 69:438–447
Sugiyama K, Azuhata Y, Matsuura D, Kameda Y, Yokota M (1994) Antitumor-promoting effect of Kampo formulations on rat urinary bladder carcinogenesis in a short-term test with concanavalin. J Trad Med 11:148–155
Sugiyama K, Azuhata Y, Matsuura D (1994) Antitumor promoting effect of components of Chorei-to on rat urinary bladder carcinogenesis in a short-term test with concanavalin. J Trad Med 11:214–219
Yazawa Y, Yokota M, Sugiyama K (2000) Antitumor promoting effect of an active component of Polyporus, ergosterol and related compounds on rat urinary bladder carcinogenesis in a short-term test with concanavalin A. Biol Pharm Bull 23:1298–1302
Homma Y, Kakizoe T, Samma S, Oyasu R (1987) Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by alpha-difluoromethylornithine. Cancer Res 47:6176–6179
Kakizoe T, Kawachi T, Okada M (1978) Concanavalin A agglutination of bladder cells of rats treated with bladder carcinogens; a rapid new test to detect bladder carcinogens A. Cancer Lett 5:285–290
Kakizoe T, Hasegawa F, Kawachi T, Sugimura T (1977) Isolation of transitional epithelial cells from the rat urinary bladder. Invest Urol 15:242–244
Kakizoe T, Komatsu H, Niijima T, Kawachi T, Sugimura T (1980) Increased agglutinability of bladder cells by concanavalin A after administration of carcinogens. Cancer Res 40:2006–2009
Ohtsubo T, Kageyama R, Koseki Y, Hagi J, Kotani A, Yamamoto K, Kusu F, Miura T, Hakamata H (2016) Determination of serum brassicasterol in spontaneously hypertensive rats stroke-prone fed a high-ergosterol diet by ultra performance liquid chromatography. Eur J Lipid Sci Technol 118:1074–1083
Tsugawa N, Okano T, Takeuchi A, Kayama M, Kobayashi T (1992) Metabolism of orally administered ergosterol and 7-dehydrocholesterol in rats and lack of evidence for their vitamin D biological activity. J Nutr Sci Vitaminol (Tokyo) 38:15–25
Cohen SM, Arai M, Jacobs JB, Friedell GH (1979) Promoting effect of saccharin and dl-tryptophan in urinary bladder carcinogenesis. Cancer Res 39:1207–1217
Cohen SM, Cano M, Earl RA, Carson SD, Garland EM (1991) A proposed role for silicates and protein in the proliferative effects of saccharin on the male rat urothelium. Carcinogenesis 12:1551–1555
Garland EM, St John M, Asamoto M, Eklund SH, Mattson BJ, Johnson LS, Cano M, Cohen SM (1994) A comparison of the effects of sodium saccharin in NBR rats and in intact and castrated male F344 rats. Cancer Lett 78:99–107
Dunning WF, Curtis MR, Maun ME (1950) The effect of added dietary tryptophane on the occurrence of 2-acetylaminofluorene-induced liver and bladder cancer in rats. Cancer Res 10:454–459
Hiraku Y, Inoue S, Oikawa S, Yamamoto K, Tada S, Nishino K, Kawanishi S (1995) Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis 16:349–356
Airoldi L, Magagnotti C, Bonfanti M, Chiappetta L, Lolli M, Medana C, De Gregorio G, Fanelli R (1994) Detection of O6-butyl- and O6-(4-hydroxybutyl)guanine in urothelial and hepatic DNA of rats given the bladder carcinogen N-nitrosobutyl(4-hydroxybutyl)amine. Carcinogenesis 15:2297–2301
Ito N, Hiasa Y, Tamai A, Okajima E, Kitamura H (1969) Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gan 60:401–410
Suzuki E, Okada M (1980) Metabolic fate of N-butyl-N-(4-hydroxybutyl) nitrosamine in the rat. Gan 71:856–862
Li Y, Izumi K, Miyamoto H (2012) The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 42:569–577
Bertram JS, Craig AW (1972) Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 8:587–594
Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S (1975) Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 3:73–79
Chang CS, Kokontis J, Liao ST (1988) Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324–326
Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T (1997) Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 31:360–364
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–568
Conflict of interest
The authors declare that there are no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yazawa, Y., Ikarashi, N., Hoshino, M. et al. Inhibitory effect of ergosterol on bladder carcinogenesis is due to androgen signaling inhibition by brassicasterol, a metabolite of ergosterol. J Nat Med (2020). https://doi.org/10.1007/s11418-020-01419-4
- Bladder carcinogenesis
- Androgen signal